Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gain Therapeutics Inc (NQ: GANX )

2.425 +0.245 (+11.24%)
Streaming Delayed Price Updated: 1:28 PM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gain Therapeutics Inc

< Previous 1 2 3 4 5 Next >
Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option
From Gain Therapeutics, Inc.
Via GlobeNewswire
Why American Eagle Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of American Eagle Outfitters, Inc. (NYSE: AEO) declined during Tuesday’s session after the company reported third-quarter financial results. Net revenue rose 5% Y/Y to $1.30 billion, beating the... 
Via Benzinga
Expert Ratings for Gain Therapeutics
Via Benzinga
Chardan Capital Maintains Buy Rating for Gain Therapeutics: Here's What You Need To Know
Via Benzinga
Where Gain Therapeutics Stands With Analysts
Via Benzinga
Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants
From Gain Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Gain Therapeutics Announces Proposed Public Offering
From Gain Therapeutics, Inc.
Via GlobeNewswire
Analyst Expectations for Gain Therapeutics's Future
Via Benzinga
Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
Phase 1 clinical study of GT-02287 initiated; dosing escalation on schedule 
From Gain Therapeutics, Inc.
Via GlobeNewswire
These Apple Insiders Are Selling Shares of AAPL Stock
Apple stock is on the move Wednesday after several insiders at the company, including CEO Tim Cook, sold shares of AAPL. 
Via InvestorPlace
Why Is Nvni Group (NVNI) Stock Down 8% Today?
Nvni Group is seeing shares of NVNI stock fall on Wednesday following the company's debut debut yesterday following a SPAC merger. 
Via InvestorPlace
Why Is Gain Therapeutics (GANX) Stock Moving Today?
Gain Therapeutics stock is on the move Wednesday as investors in GANX react to updated clinical trial news from the company. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday. 
Via InvestorPlace
Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
First small molecule allosteric binder discovered with Gain’s computational drug discovery platform enters clinical development 
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Present at the Cambridge Healthtech Institute’s 2nd Annual Neurodegeneration Targets Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2023
Via Benzinga
Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research
Via Get News
Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research
--News Direct-- 
Via News Direct
Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research
Bethesda, MD, August 29, 2023 (PlatoData via 500NewsWire) -- Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies,... 
Via TheNewswire.com
Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson’s Disease Model
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Acceptance of Late Breaking Abstract for Presentation at the International Congress of Parkinson’s Disease and Movement Disorders®
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate in the 2023 BTIG Virtual Biotechnology Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Present at the Jefferies Healthcare Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer
From Gain Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.